Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.

Kato MK, Yunokawa M, Bun S, Shimoi T, Yonemori K, Miyasaka N, Kato T, Tamura K.

J Cancer Res Clin Oncol. 2020 Mar 6. doi: 10.1007/s00432-020-03168-z. [Epub ahead of print]

PMID:
32144536
2.

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H.

Breast Cancer. 2020 Feb 11. doi: 10.1007/s12282-020-01054-7. [Epub ahead of print]

PMID:
32043218
3.

A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population.

Nakano MH, Udagawa C, Shimo A, Kojima Y, Yoshie R, Zaha H, Abe N, Motonari T, Unesoko M, Tamura K, Shimoi T, Yoshida M, Yoshida T, Sakamoto H, Kato K, Mushiroda T, Tsugawa K, Zembutsu H.

Biol Pharm Bull. 2019 Dec 1;42(12):2045-2053. doi: 10.1248/bpb.b19-00527. Epub 2019 Oct 9.

4.

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan.

Yunokawa M, Sasada S, Takehara Y, Takahashi K, Shimoi T, Yonemori K, Ishikawa M, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1051-1058. doi: 10.1007/s00280-019-03938-8. Epub 2019 Sep 4.

PMID:
31482227
5.

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.

Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.

PMID:
31104192
6.

Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study.

Bun S, Yunokawa M, Ebata T, Kobayashi Kato M, Shimoi T, Kato T, Tamura K.

Int J Clin Oncol. 2019 Sep;24(9):1111-1118. doi: 10.1007/s10147-019-01449-3. Epub 2019 Apr 15.

PMID:
30993482
7.

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.

Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8.

8.

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.

Intern Med. 2019 May 15;58(10):1423-1428. doi: 10.2169/internalmedicine.1118-18. Epub 2019 Feb 1.

9.

Impact of Surgical Margin in Skull Base Surgery for Head and Neck Sarcomas.

Kobayashi K, Matsumoto F, Miyakita Y, Mori T, Shimoi T, Murakami N, Yoshida A, Arakawa A, Omura G, Fukasawa M, Matsumoto Y, Matsumura S, Itami J, Narita Y, Yoshimoto S.

J Neurol Surg B Skull Base. 2018 Oct;79(5):437-444. doi: 10.1055/s-0037-1615816. Epub 2018 Jan 9.

10.

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.

Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K.

Cancer Sci. 2018 Aug;109(8):2558-2566. doi: 10.1111/cas.13696. Epub 2018 Jul 28.

11.

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.

Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 10.1007/s00280-018-3617-5. Epub 2018 Jun 5.

12.

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.

Ebata T, Shimoi T, Bun S, Miyake M, Yoshida A, Shimomura A, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Narita Y, Tamura K.

Oncology. 2018;94(6):340-344. doi: 10.1159/000486623. Epub 2018 Apr 3.

PMID:
29614488
13.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

14.

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.

Support Care Cancer. 2018 Jul;26(7):2161-2166. doi: 10.1007/s00520-018-4054-z. Epub 2018 Jan 25.

PMID:
29372396
15.

Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.

Udagawa C, Nakamura H, Ohnishi H, Tamura K, Shimoi T, Yoshida M, Yoshida T, Totoki Y, Shibata T, Zembutsu H.

Cancer Sci. 2018 Feb;109(2):446-452. doi: 10.1111/cas.13471. Epub 2018 Jan 24.

16.

TERT promoter hotspot mutations in breast cancer.

Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.

Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8.

17.

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8.

18.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.

Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Yoshida A, Fujiwara Y, Tamura K.

Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.

PMID:
29176397
19.

The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.

Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Int J Gynecol Cancer. 2017 Nov;27(9):1850-1855. doi: 10.1097/IGC.0000000000001107.

PMID:
29040183
20.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
21.

The Use of PET/CT and Bone Marrow Aspiration/Biopsy in Initial Staging Evaluation of Adolescent and Adult Ewing Sarcomas.

Inagaki C, Shimoi T, Okuma H, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Ann Oncol. 2017 Oct;28 Suppl 9:ix100. doi: 10.1093/annonc/mdx621.021. No abstract available.

22.

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

23.

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3. No abstract available.

PMID:
28770275
24.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.

Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K.

ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.

25.

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.

Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K.

Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21.

PMID:
28733700
26.

Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.

Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K.

Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.

27.

Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.

Yunokawa M, Yoshida H, Watanabe R, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2017 Jul;80(1):127-134. doi: 10.1007/s00280-017-3342-5. Epub 2017 May 24.

PMID:
28540420
28.

Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.

Ebata T, Shimoi T, Ishiwata T, Iwasawa S, Bun S, Yunokawa M, Yonemori K, Takiguchi Y, Tamura K.

Oncology. 2017;93(3):177-182. doi: 10.1159/000475669. Epub 2017 May 19.

PMID:
28521313
29.

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. No abstract available.

30.

Crystal Engineering of Self-Assembled Porous Protein Materials in Living Cells.

Abe S, Tabe H, Ijiri H, Yamashita K, Hirata K, Atsumi K, Shimoi T, Akai M, Mori H, Kitagawa S, Ueno T.

ACS Nano. 2017 Mar 28;11(3):2410-2419. doi: 10.1021/acsnano.6b06099. Epub 2017 Feb 9.

PMID:
28094987
31.

Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.

Ebata T, Yunokawa M, Bun S, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1283-1288. doi: 10.1007/s00280-016-3187-3. Epub 2016 Nov 10.

PMID:
27832327
32.

Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.

Bun S, Yunokawa M, Ebata T, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Makino Y, Hayashi Y, Tamura K.

Cancer Chemother Pharmacol. 2016 Oct;78(4):745-52. doi: 10.1007/s00280-016-3100-0. Epub 2016 Aug 13.

PMID:
27522647
33.

Development of an interprofessional competency framework in Japan.

Haruta J, Sakai I, Otsuka M, Yoshimoto H, Yoshida K, Goto M, Shimoi T.

J Interprof Care. 2016 Sep;30(5):675-7. doi: 10.1080/13561820.2016.1192588. Epub 2016 Jun 28.

PMID:
27351518
34.

Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults.

Sasada S, Kodaira M, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Anticancer Res. 2016 May;36(5):2429-32.

PMID:
27127153
35.

Photoactivatable CO release from engineered protein crystals to modulate NF-κB activation.

Tabe H, Shimoi T, Boudes M, Abe S, Coulibaly F, Kitagawa S, Mori H, Ueno T.

Chem Commun (Camb). 2016 Mar 25;52(24):4545-8. doi: 10.1039/c5cc10440h.

PMID:
26940021
36.

Identification of oscillatory firing neurons associated with locomotion in the earthworm through synapse imaging.

Shimoi T, Mizutani K, Kojima D, Kitamura Y, Hotta K, Ogawa H, Oka K.

Neuroscience. 2014 May 30;268:149-58. doi: 10.1016/j.neuroscience.2014.03.016. Epub 2014 Mar 19.

PMID:
24657777
37.

The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT.

Shimoi T, Ando M, Munakata W, Kobayashi T, Kakihana K, Ohashi K, Akiyama H, Sakamaki H.

Bone Marrow Transplant. 2013 Jan;48(1):80-4. doi: 10.1038/bmt.2012.85. Epub 2012 May 28.

PMID:
22635246
38.

Clinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patients.

Shimoi T, Shojima K, Murota A, Takizawa Y, Maruyama J, Setoguchi K.

Asian Pac J Allergy Immunol. 2012 Mar;30(1):61-70.

39.

Effects of serotonergic anxiolytics on the freezing behavior in the elevated open-platform test in mice.

Miyata S, Shimoi T, Hirano S, Yamada N, Hata Y, Yoshikawa N, Ohsawa M, Kamei J.

J Pharmacol Sci. 2007 Nov;105(3):272-8. Epub 2007 Oct 27.

40.

[Survey of glycoalkaloids content in the various potatoes].

Shimoi T, Ushiyama H, Kan K, Saito K, Kamata K, Hirokado M.

Shokuhin Eiseigaku Zasshi. 2007 Jun;48(3):77-82. Japanese.

41.

[Example of examination of allergic substances (egg, milk) in commercial foods].

Shimoi T, Ushiyama H, Kan K, Saito K, Kamata K.

Shokuhin Eiseigaku Zasshi. 2006 Aug;47(4):189-95. Japanese.

42.

[The problem and improvement of colorimetric method for determination of sulfite in foods containing sulfur compounds].

Shimoi T, Ibe A, Tabata S, Suzuki J, Sadamasu Y, Yasui A, Saito K.

Shokuhin Eiseigaku Zasshi. 2004 Dec;45(6):332-8. Japanese.

43.

Influence of mRNA and protein synthesis inhibitors on the long-term memory acquisition of classically conditioned earthworms.

Watanabe H, Takaya T, Shimoi T, Ogawa H, Kitamura Y, Oka K.

Neurobiol Learn Mem. 2005 Mar;83(2):151-7.

PMID:
15721799
44.

Modulation of motor patterns by sensory feedback during earthworm locomotion.

Mizutani K, Shimoi T, Ogawa H, Kitamura Y, Oka K.

Neurosci Res. 2004 Apr;48(4):457-62.

PMID:
15041199
45.

[Production of tyramine in "moromi" mash during soy sauce fermentation].

Ibe A, Tabata S, Sadamasu Y, Yasui A, Shimoi T, Endoh M, Saito K.

Shokuhin Eiseigaku Zasshi. 2003 Oct;44(5):220-6. Japanese.

46.

Identification of two types of synaptic activity in the earthworm nervous system during locomotion.

Mizutani K, Shimoi T, Kitamura Y, Ogawa H, Oka K.

Neuroscience. 2003;121(2):473-8.

PMID:
14522005
47.

Studies on the pathogenesis of stress ulcers.

Shimoi T.

Nihon Geka Hokan. 1981 Mar 1;50(2):253-71. No abstract available.

PMID:
7283619

Supplemental Content

Loading ...
Support Center